论文部分内容阅读
背景与目的:肾细胞癌是一种对免疫治疗敏感的肿瘤,包括了非清髓性异基因移植。然而由于严重的毒性,许多转移性肾细胞癌并不适合非清髓性异基因移植。这促使了其他一些新的异基因免疫治疗的发展。本研究评价输注经照射的HLA部分相合的异基因单个核细胞治疗晚期肾细胞癌的有效性和安全性。方法:选择经病理证实的晚期肾细胞癌患者,予输注经照射的HLA部分相合的异基因单个核细胞。每2个月输注1次,治疗有效或稳定者继续输注,直至疾病进展或出现不能耐受的不良反应或患者(或供者)拒绝继续使用。结果:8例患者进入本研究。6例患者每次输注后每日口服沙利度胺100mg至300mg两个月,1例达到持久的完全缓解(CR),5例稳定(SD),2例进展(PD)。8例患者的中位疾病无进展时间为292d,中位生存时间为879d以上。毒性反应轻微。结论:输注经照射的HLA部分相合的异基因单个核细胞治疗晚期肾细胞癌有了一定疗效,值得进一步研究。
BACKGROUND & AIM: Renal cell carcinoma is a tumor that is immunosuppressive and includes non-myeloablative allogeneic transplantation. However, due to the severe toxicity, many metastatic renal cell carcinomas are not suitable for non-myeloablative allogeneic transplantation. This prompted the development of several other new allogeneic immunotherapies. This study evaluated the efficacy and safety of irradiated irradiated HLA-matched allogeneic mononuclear cells in the treatment of advanced renal cell carcinoma. Methods: Patients with pathologically confirmed advanced renal cell carcinoma were selected and infused with HLA-matched, allogeneic mononuclear cells. Infusion once every 2 months, treatment is effective or stable infusion continue until the disease progression or intolerable adverse reactions or patients (or donor) refuses to continue to use. Results: Eight patients entered the study. Six patients were treated with thalidomide 100 mg to 300 mg twice daily after each infusion. One patient achieved long-term complete remission (CR), five stable (SD) and two progressive (PD) patients. The median progression-free time was 292 days in 8 patients and the median survival time was 879 days. Toxicity is mild. Conclusion: Irradiated HLA-matched allogeneic mononuclear cells have some efficacy in the treatment of advanced renal cell carcinoma, which deserves further study.